Investing
Bitcoin and other cryptocurrencies were little changed Wednesday as the digital asset market steadied after a recent selloff ushered in the biggest one-day decline...
Hi, what are you looking for?
IntelTEXTA
IntelTEXTA
Investing
Don’t miss these top money and investing features: Sign up here to get MarketWatch’s highlights of the most timely ETF news emailed to you weekly....
Investing
In these times of deep divisions, one thing Americans can agree on is the Super Bowl. It has become our secular version of Carnival...
Investing
A glimmer of hope appeared Friday for beleaguered New York Community Bancorp after its stock rose 17% on strong trading volume. Investors seemed reassured...
Investing
Nvidia Corp. shares rallied in the extended session Wednesday after the maker of graphics processing units that is leading the AI-hardware charge reported a...
Investing
Shares of Splunk Inc. jumped 12% in extended trading Wednesday after the software company reported quarterly results that topped analysts’ revenue and earnings estimates....
Investing
Nvidia Corp. stunned Wall Street with Wednesday’s jaw-dropping forecast of $16 billion in revenue for the current quarter, and that may not even be...
Investing
Snowflake Inc. broke from its pattern of outlook cuts Wednesday afternoon as it kept its forecast for the full year steady, and its shares...
Investing
All large cryptocurrencies were up during morning trading on Wednesday, with Solana SOLUSD, +0.70% seeing the biggest change, rising 2.57% to $20.75. Uniswap UNIUSD,...
Investing
Netflix Inc.’s stock surged more than 3% on Wednesday after a bullish note said the video-streaming giant has a “clear path” to jacking up...
Investing
Oil futures finished lower on Tuesday for a second straight session, with the market unable to shake worries about China’s economic outlook and the...
Investing
SYDNEY — The Australian economy continues to cool quickly with Judo Bank’s purchasing managers index for August showing a marked decline. The Judo Bank...
Investing
By Sabela Ojea Apellis Pharmaceuticals on Tuesday provided an update on the eye-disease drug Syfovre, which has been dogged by safety concerns in recent...
